Hospital
DLP Conemaugh Memorial Medical Center LLC
DLP Conemaugh Memorial Medical Center LLC was paid $18.22M by Medicaid between Jan 2018 and Dec 2024, across 422 billing codes. Its largest line is T1015, a visit at a community health center or clinic (one all-in rate) — 9.3% of everything it billed.
33Billing provider infoDLP CONEMAUGH MEMORIAL MEDICAL CENTER LLC
JOHNSTOWN, PA 15905
JOHNSTOWN, PA 15905
33aNPI1801897038assigned 08/10/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$18.22M
24GClaims618,287
24DCodes billed422
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Pennsylvania
Rank by total paid#16 of 154
Median peer was paid$2.82M
This provider vs. median6.5×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official LAWRENCE, CHARLOTTE controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 869 | $15K | |
| 2019 | 1,312 | $19K | |
| 2020 | 60,233 | $1.64M | |
| 2021 | 296,014 | $8.80M | |
| 2022 | 88,360 | $2.91M | |
| 2023 | 92,208 | $2.55M | |
| 2024incomplete | 79,291 | $2.28M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| T1015 | A visit at a community health center or clinic (one all-in rate)Clinic visit/encounter, all-inclusive | 9.3% | 26,484 | 21,828 | $1.69M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 9.2% | 10,771 | 10,459 | $1.68M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 7.8% | 12,227 | 11,880 | $1.41M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 7.7% | 17,468 | 16,999 | $1.41M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 7.7% | 15,082 | 14,196 | $1.40M |
| G0378 | Hospital observation service, per hour | 3.5% | 980 | 704 | $640K |
| X0621 | 3.0% | 2,319 | 1,657 | $554K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.2% | 2,526 | 2,465 | $409K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 1.5% | 13,537 | 12,770 | $277K |
| 36415 | Collection of venous blood by venipuncture | 1.5% | 64,858 | 56,094 | $269K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | 1.4% | 3,078 | 2,837 | $259K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.4% | 6,455 | 6,332 | $257K |
410 more codes
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 1.4% | 5,423 | $248K |
| 93976 | 1.1% | 2,388 | $201K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.1% | 3,792 | $196K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 1.0% | 4,484 | $190K |
| 84443 | Thyroid stimulating hormone (TSH) | 1.0% | 7,656 | $185K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 2,796 | $174K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 29,764 | $168K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 19,234 | $165K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 11,294 | $163K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 3,307 | $159K |
| 80053 | Comprehensive metabolic panel | <1% | 13,155 | $154K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 2,426 | $141K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 4,904 | $134K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 3,643 | $131K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 2,927 | $126K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 4,610 | $118K |
| 62323 | <1% | 1,123 | $115K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 3,023 | $114K |
| 80061 | Lipid panel | <1% | 7,437 | $109K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 1,763 | $104K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 402 | $101K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 2,378 | $99K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 561 | $97K |
| 80050 | General health panel | <1% | 1,943 | $96K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 6,457 | $93K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 995 | $90K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 1,206 | $90K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 2,821 | $90K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 1,858 | $88K |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 821 | $80K |
| 84484 | <1% | 9,464 | $80K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 271 | $77K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 6,674 | $76K |
| 83735 | <1% | 11,584 | $73K | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 54 | $73K |
| 11043 | <1% | 741 | $72K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 1,686 | $72K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 413 | $71K |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 77 | $69K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,808 | $67K |
| 74183 | <1% | 173 | $66K | |
| 84703 | <1% | 6,064 | $64K | |
| 76830 | Ultrasound, transvaginal | <1% | 1,213 | $60K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 7,512 | $58K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,362 | $58K |
| 84100 | <1% | 10,180 | $57K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 6,444 | $55K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 305 | $54K |
| 86780 | <1% | 3,085 | $54K | |
| 85027 | <1% | 6,579 | $51K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 4,383 | $48K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 422 | $47K |
| 84439 | <1% | 5,703 | $47K | |
| 80076 | <1% | 5,255 | $47K | |
| 0002A | <1% | 970 | $45K | |
| 76821 | <1% | 741 | $45K | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 560 | $44K |
| 76820 | <1% | 1,500 | $43K | |
| 0001A | <1% | 1,048 | $42K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 5,896 | $42K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 523 | $41K |
| 72141 | <1% | 179 | $40K | |
| 87150 | <1% | 770 | $38K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 176 | $37K |
| 88342 | <1% | 879 | $34K | |
| 84702 | <1% | 1,669 | $32K | |
| 71250 | <1% | 506 | $30K | |
| 88341 | <1% | 559 | $30K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 453 | $28K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,368 | $28K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 515 | $28K |
| 83615 | <1% | 3,750 | $27K | |
| 93970 | <1% | 312 | $27K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 1,064 | $26K |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | <1% | 2,407 | $26K |
| 86803 | <1% | 1,195 | $26K | |
| 80074 | <1% | 430 | $26K | |
| 83690 | <1% | 5,429 | $26K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 2,090 | $25K |
| 87081 | <1% | 3,995 | $25K | |
| 81001 | <1% | 8,017 | $24K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 506 | $24K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 137 | $24K |
| 93880 | <1% | 353 | $23K | |
| 76642 | <1% | 508 | $23K | |
| 12001 | <1% | 166 | $23K | |
| 93000 | <1% | 1,194 | $22K | |
| 82607 | <1% | 1,633 | $22K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 9,534 | $22K |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 443 | $21K |
| C1769 | Guide wire | <1% | 588 | $20K |
| 64721 | <1% | 40 | $20K | |
| 77066 | Tomosynthesis, mammo | <1% | 206 | $20K |
| 83605 | <1% | 2,886 | $20K | |
| G0444 | Annual depression screening, 5 to 15 minutes | <1% | 882 | $19K |
| 76536 | <1% | 386 | $19K | |
| G0399 | Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation | <1% | 142 | $19K |
| 97162 | <1% | 387 | $18K | |
| 86762 | <1% | 770 | $18K | |
| 83516 | <1% | 279 | $17K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 82 | $17K |
| 87340 | <1% | 1,042 | $17K | |
| 87077 | <1% | 2,039 | $17K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 455 | $17K |
| 87522 | Neg quan hep c or qual rna | <1% | 348 | $16K |
| M0245 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring | <1% | 43 | $16K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 672 | $16K |
| X0592 | <1% | 377 | $16K | |
| 93017 | <1% | 417 | $15K | |
| 93971 | <1% | 219 | $15K | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 291 | $15K |
| 82728 | <1% | 1,149 | $15K | |
| 83970 | <1% | 324 | $14K | |
| 76801 | <1% | 313 | $14K | |
| 83880 | <1% | 591 | $14K | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 63 | $14K |
| 93923 | <1% | 268 | $14K | |
| 73221 | <1% | 56 | $14K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 2,143 | $14K |
| 86618 | <1% | 516 | $14K | |
| 76770 | <1% | 322 | $14K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,855 | $13K |
| 82570 | <1% | 1,695 | $13K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 167 | $13K |
| 73564 | <1% | 548 | $13K | |
| 95811 | <1% | 27 | $13K | |
| 87536 | <1% | 97 | $13K | |
| 84112 | <1% | 121 | $13K | |
| 73610 | <1% | 602 | $12K | |
| 86850 | <1% | 1,434 | $12K | |
| 93325 | <1% | 148 | $12K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 38 | $11K |
| 82746 | <1% | 933 | $11K | |
| 81003 | <1% | 3,640 | $11K | |
| 87186 | <1% | 1,270 | $11K | |
| 84153 | <1% | 385 | $11K | |
| 84144 | <1% | 509 | $11K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 188 | $10K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 216 | $10K |
| 84146 | <1% | 373 | $10K | |
| 70486 | <1% | 138 | $10K | |
| 83540 | <1% | 1,057 | $10K | |
| 75574 | <1% | 54 | $10K | |
| 82043 | <1% | 1,096 | $10K | |
| 73630 | <1% | 787 | $10K | |
| 77065 | Tomosynthesis, mammo | <1% | 150 | $9K |
| 94729 | <1% | 345 | $9K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 692 | $9K |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 1,879 | $9K |
| 85610 | <1% | 2,731 | $9K | |
| 72100 | <1% | 453 | $9K | |
| 84403 | <1% | 286 | $9K | |
| 81420 | Fetal chromosomal aneuploidy genomic sequence analysis panel | <1% | 13 | $9K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 840 | $9K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 177 | $9K |
| 73030 | <1% | 553 | $9K | |
| 87040 | <1% | 816 | $8K | |
| 71271 | <1% | 86 | $8K | |
| 84481 | <1% | 316 | $8K | |
| 84460 | <1% | 1,006 | $8K | |
| J0585 | Injection, onabotulinumtoxina, 1 unit | <1% | 330 | $7K |
| 73130 | <1% | 570 | $7K | |
| 86038 | <1% | 417 | $7K | |
| G0008 | Administration of influenza virus vaccine | <1% | 739 | $7K |
| 72110 | <1% | 328 | $7K | |
| 87070 | <1% | 1,016 | $7K | |
| 84550 | <1% | 1,031 | $7K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 190 | $7K |
| 84450 | <1% | 976 | $7K | |
| 72197 | <1% | 12 | $7K | |
| 94726 | <1% | 259 | $6K | |
| 84466 | <1% | 331 | $6K | |
| 73502 | <1% | 302 | $6K | |
| 82565 | <1% | 929 | $6K | |
| 74018 | <1% | 393 | $6K | |
| 93226 | <1% | 157 | $6K | |
| 12002 | <1% | 27 | $6K | |
| 85730 | <1% | 1,088 | $5K | |
| 86900 | <1% | 1,290 | $5K | |
| 86901 | <1% | 1,267 | $5K | |
| 70491 | <1% | 72 | $5K | |
| 86360 | <1% | 73 | $5K | |
| 87205 | <1% | 1,024 | $5K | |
| 87807 | <1% | 331 | $5K | |
| J2791 | Injection, rho(d) immune globulin (human), (rhophylac), intramuscular or intravenous, 100 iu | <1% | 97 | $5K |
| 85652 | <1% | 1,535 | $5K | |
| 87210 | <1% | 473 | $5K | |
| 84270 | <1% | 155 | $5K | |
| 86147 | <1% | 95 | $5K | |
| 73110 | <1% | 393 | $5K | |
| 85379 | <1% | 468 | $5K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 838 | $5K |
| 85007 | <1% | 1,114 | $5K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 409 | $4K |
| 86800 | <1% | 212 | $4K | |
| 87899 | <1% | 110 | $4K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 315 | $4K |
| 83655 | <1% | 336 | $4K | |
| 93458 | <1% | 12 | $4K | |
| 59025 | Fetal non-stress test | <1% | 725 | $4K |
| 82550 | <1% | 865 | $4K | |
| 82950 | <1% | 534 | $4K | |
| 64615 | <1% | 37 | $4K | |
| 86235 | <1% | 47 | $4K | |
| 86146 | <1% | 77 | $4K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 197 | $4K |
| 83001 | <1% | 184 | $4K | |
| 94060 | <1% | 396 | $4K | |
| 71045 | Radiologic examination, chest; single view | <1% | 661 | $4K |
| 76827 | <1% | 81 | $4K | |
| 73590 | <1% | 215 | $4K | |
| 86359 | <1% | 73 | $4K | |
| 82803 | <1% | 162 | $3K | |
| J2704 | Injection, propofol, 10 mg | <1% | 6,809 | $3K |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 1,205 | $3K |
| 86376 | <1% | 365 | $3K | |
| 90686 | <1% | 747 | $3K | |
| 72040 | <1% | 219 | $3K | |
| 82248 | <1% | 485 | $3K | |
| 82533 | <1% | 236 | $3K | |
| 86140 | <1% | 1,027 | $3K | |
| Q9969 | Tc-99m from non-highly enriched uranium source, full cost recovery add-on, per study dose | <1% | 456 | $3K |
| 73562 | <1% | 169 | $3K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 5,734 | $3K |
| 86706 | <1% | 190 | $3K | |
| 82784 | <1% | 104 | $3K | |
| 93225 | <1% | 158 | $3K | |
| J1815 | Injection, insulin, per 5 units | <1% | 141 | $3K |
| 0004A | <1% | 59 | $3K | |
| 84480 | <1% | 296 | $3K | |
| 84156 | <1% | 560 | $3K | |
| 84436 | <1% | 242 | $3K | |
| 73090 | <1% | 195 | $2K | |
| 62321 | <1% | 29 | $2K | |
| 80069 | <1% | 227 | $2K | |
| 73080 | <1% | 208 | $2K | |
| 80164 | <1% | 137 | $2K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 41 | $2K |
| 86430 | <1% | 285 | $2K | |
| 27096 | <1% | 27 | $2K | |
| 83550 | <1% | 434 | $2K | |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 24 | $2K |
| 76825 | <1% | 95 | $2K | |
| 0124A | <1% | 58 | $2K | |
| 20553 | <1% | 70 | $2K | |
| 43235 | <1% | 24 | $2K | |
| 96376 | <1% | 256 | $2K | |
| 10061 | <1% | 13 | $2K | |
| 85018 | <1% | 564 | $2K | |
| 82670 | <1% | 69 | $2K | |
| 85014 | <1% | 522 | $2K | |
| 80051 | <1% | 275 | $2K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 66 | $2K |
| J2310 | Injection, naloxone hydrochloride, per 1 mg | <1% | 102 | $2K |
| 76641 | <1% | 29 | $2K | |
| 84520 | <1% | 322 | $2K | |
| 76870 | <1% | 38 | $2K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,060 | $2K |
| 82947 | <1% | 419 | $2K | |
| 82150 | <1% | 345 | $2K | |
| 97166 | <1% | 73 | $2K | |
| 87493 | <1% | 46 | $2K | |
| 82948 | <1% | 1,959 | $2K | |
| 85613 | <1% | 105 | $1K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 185 | $1K |
| 86617 | <1% | 32 | $1K | |
| 83002 | <1% | 68 | $1K | |
| 90714 | <1% | 215 | $1K | |
| 76376 | <1% | 12 | $1K | |
| 86200 | <1% | 81 | $1K | |
| 72050 | <1% | 53 | $1K | |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 99 | $1K |
| 81511 | <1% | 13 | $1K | |
| 82553 | <1% | 261 | $1K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 3,435 | $1K |
| 88142 | <1% | 57 | $1K | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 459 | $1K |
| G0328 | Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous | <1% | 66 | $1K |
| 73560 | <1% | 73 | $1K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 26 | $1K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 12 | $1K |
| 83721 | <1% | 107 | $1K | |
| 95816 | <1% | 87 | $1K | |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | <1% | 28 | $990.64 |
| 97165 | <1% | 27 | $986.77 | |
| 82977 | <1% | 101 | $935.69 | |
| 29125 | <1% | 69 | $932.10 | |
| 82951 | <1% | 59 | $889.48 | |
| Q9957 | Injection, perflutren lipid microspheres, per ml | <1% | 13 | $830.28 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 385 | $830.06 |
| 87046 | <1% | 187 | $809.41 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 3,268 | $792.69 |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 31 | $786.45 |
| 87328 | <1% | 29 | $751.64 | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 237 | $743.90 |
| 77080 | <1% | 12 | $734.40 | |
| 82627 | <1% | 29 | $728.07 | |
| 87106 | <1% | 60 | $669.12 | |
| 20610 | <1% | 33 | $654.41 | |
| 83874 | <1% | 58 | $590.10 | |
| 86308 | <1% | 72 | $580.43 | |
| 87045 | <1% | 93 | $569.29 | |
| 96127 | <1% | 141 | $545.00 | |
| 87015 | <1% | 86 | $504.27 | |
| 86923 | <1% | 14 | $501.90 | |
| 85045 | <1% | 120 | $491.15 | |
| 86225 | <1% | 28 | $480.90 | |
| 71101 | <1% | 29 | $480.86 | |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 488 | $479.28 |
| 84132 | <1% | 104 | $471.78 | |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | <1% | 25 | $468.56 |
| 72052 | <1% | 16 | $465.53 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 90 | $445.76 |
| S9470 | Nutritional counseling, dietitian visit | <1% | 14 | $433.84 |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 177 | $433.19 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 4,859 | $394.65 |
| S0028 | Injection, famotidine, 20 mg | <1% | 575 | $393.66 |
| 83520 | <1% | 14 | $390.35 | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 57 | $373.46 |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 66 | $365.41 |
| 83525 | <1% | 25 | $364.32 | |
| 80178 | <1% | 43 | $363.77 | |
| 90688 | <1% | 59 | $362.50 | |
| 86696 | <1% | 14 | $361.87 | |
| 87329 | <1% | 29 | $349.16 | |
| 73060 | <1% | 40 | $347.26 | |
| 76857 | <1% | 16 | $341.41 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 42 | $331.00 |
| 94760 | <1% | 347 | $329.69 | |
| 86787 | <1% | 14 | $323.59 | |
| 84165 | <1% | 27 | $323.26 | |
| G0009 | Administration of pneumococcal vaccine | <1% | 28 | $318.40 |
| 88112 | <1% | 12 | $318.23 | |
| 97161 | <1% | 12 | $309.59 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 452 | $300.18 |
| 83090 | <1% | 16 | $291.93 | |
| 73552 | <1% | 17 | $291.61 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 851 | $288.64 |
| 85306 | <1% | 13 | $286.39 | |
| 86695 | <1% | 14 | $285.30 | |
| 86694 | <1% | 13 | $283.13 | |
| 84145 | <1% | 32 | $274.50 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 334 | $274.13 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 3,135 | $273.62 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,247 | $269.74 |
| 12011 | <1% | 39 | $269.36 | |
| 72170 | <1% | 32 | $265.10 | |
| 73140 | <1% | 26 | $264.69 | |
| 90715 | <1% | 61 | $239.05 | |
| 86704 | <1% | 14 | $234.90 | |
| 82952 | <1% | 59 | $232.71 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 441 | $230.97 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,368 | $225.46 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 673 | $217.41 |
| 86769 | <1% | 15 | $211.48 | |
| 86708 | <1% | 12 | $198.83 | |
| 82247 | <1% | 34 | $195.93 | |
| 80197 | <1% | 18 | $174.63 | |
| 82105 | <1% | 12 | $167.15 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 253 | $162.53 |
| 88304 | <1% | 208 | $157.45 | |
| 36600 | <1% | 28 | $152.08 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 1,984 | $151.36 |
| 92551 | <1% | 24 | $133.48 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 152 | $128.84 |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 106 | $127.36 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 141 | $119.70 |
| 82010 | <1% | 36 | $116.89 | |
| 88307 | <1% | 28 | $116.53 | |
| 84155 | <1% | 29 | $107.20 | |
| 89055 | <1% | 28 | $106.93 | |
| 99173 | <1% | 24 | $97.11 | |
| S0077 | Injection, clindamycin phosphate, 300 mg | <1% | 23 | $86.15 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 352 | $84.87 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 286 | $83.98 |
| 82330 | <1% | 15 | $81.53 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 411 | $70.28 |
| C1766 | Introducer/sheath, guiding, intracardiac electrophysiological, steerable, other than peel-away | <1% | 28 | $66.92 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 268 | $59.52 |
| 82140 | <1% | 13 | $48.40 | |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | <1% | 14 | $45.37 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 2,061 | $44.54 |
| 82040 | <1% | 12 | $43.50 | |
| G0145 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision | <1% | 17 | $35.18 |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 41 | $33.32 |
| 81002 | <1% | 15 | $26.87 | |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | <1% | 425 | $25.24 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 12 | $16.77 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 30 | $1.10 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 684 | $0.12 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 484 | $0.00 |
| 91312 | 0% | 218 | $0.00 | |
| 90710 | 0% | 24 | $0.00 | |
| J3370 | Injection, vancomycin hcl, 500 mg | 0% | 16 | $0.00 |
| J1756 | Injection, iron sucrose, 1 mg | 0% | 56 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 18 | $0.00 |
| 49452 | 0% | 12 | $0.00 | |
| J2916 | Injection, sodium ferric gluconate complex in sucrose injection, 12.5 mg | 0% | 19 | $0.00 |
| 90619 | 0% | 78 | $0.00 | |
| 91305 | 0% | 14 | $0.00 | |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | 0% | 24 | $0.00 |
| J1010 | Injection, methylprednisolone acetate, 1 mg | 0% | 319 | $0.00 |
| 90677 | 0% | 338 | $0.00 | |
| 90674 | 0% | 204 | $0.00 | |
| 90697 | 0% | 30 | $0.00 | |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 0% | 21 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 107 | $0.00 |
| 90656 | 0% | 211 | $0.00 | |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 15 | $0.00 |
| 90651 | 0% | 53 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialLAWRENCE, CHARLOTTE (SECRETARY)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.